J. Poirier

This study shows that DRP-104, a glutamine antagonist, suppresses KEAP1 mutant lung tumor growth and enhances response to checkpoint blockade by inhibiting glutamine metabolism and improving T cell function.

This paper demonstrates targeted ocular spectroscopy for imaging and spectral analysis of the eye fundus, showing its ability to detect biomarkers and assess blood oxygen saturation in vivo.

The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.

The paper describes the design, synthesis, and validation of a 3.7 million-member DNA-encoded library using diversity-oriented synthesis to enhance structural diversity for drug discovery.